MedTrace Logo

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

NCT06246968 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-20

No results posted yet for this study

Summary

Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.

Conditions

Interventions

DRUG

Pembrolizumab

Participants will receive Pembrolizumab as part of standard of care treatment.

DEVICE

Cryoablation

Cryoablation is a type of thermal ablation that is a minimally invasive alternative technique to surgical resection.

Sponsors & Collaborators

Principal Investigators

  • Yolanda Bryce, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-29
Primary Completion
2027-01-29
Completion
2027-01-29
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06246968 on ClinicalTrials.gov